Issue link: http://clhia.uberflip.com/i/406567
36 process with international referencing being only one of many inputs to this process; and • in the short-term, while more fundamental reform is being implemented, the list of international comparator countries be expanded to make it more representative of the entire OECD. 6. The CLHIA recommends that the PMPRB examine ways to be more aggressive in using value-based pricing approaches to setting prices. 7. The CLHIA recommends that therapeutic class price levels be reviewed periodically (e.g., every 5 years) or if increased indications result in a material change in volume (e.g., a 100 per cent increase) to ensure they reflect any material changes in the market since the prior review. 8. The CLHIA recommends that the Board of the PMPRB be required to include private insurer representation to ensure that their perspectives are considered in the overall operations of the PMPRB going forward. 9. The CLHIA recommends that the CDR/pCODR/INESS pursue opportunities to run their assessments in parallel with Health Canada and PMPRB's reviews in order to accelerate the availability of innovative drugs for Canadians. 10. The CLHIA recommends that to the extent that PLAs continue to be used by provincial governments, these lower prices should be extended to all payers. 11. The CLHIA recommends that the CDR/pCODR/INESSS mandates be expanded to include genetic tests that are tied to particular drugs and that their assessment consider the predictive value of each test as well as their relative cost-benefit when done in conjunction with a new drug.